Not exact matches
(
Free cash flow on a
per share basis is up 2 % year - over-year and stands at a strong $ 559 million for the quarter, despite a very high debt ratio of about 78 %.)
The performance goals upon which the payment or vesting of any Incentive Award (other than Options and stock appreciation rights) that is intended to qualify as Performance - Based Compensation depends shall relate to one or more of the following Performance Measures: market price of Capital Stock, earnings
per share of Capital Stock, income, net income or profit (before or after taxes), economic profit, operating income, operating margin, profit margin, gross margins, return
on equity or stockholder equity, total shareholder return, market capitalization, enterprise value,
cash flow (including but not limited to operating
cash flow and
free cash flow),
cash position, return
on assets or net assets, return
on capital, return
on invested
The company's three - year performance awards going forward are based
on both EPS and
free cash flow per share.
We believe that
free cash flow growth, especially
on a
per -
share basis, is most important to maximizing shareholder value in the long term.
Based
on that 5 - year forecast and IMS Health's tendency to buy back stock (and the reasonable price of that stock before the buyout rumor leaked) it seems likely that
free cash flow per share would have grown by 10 % + annually if IMS Health had stayed a public company.
Some of these factors include above average earnings
per -
share growth rates, above average return
on equity, excess
free cash flow, low debt - to - equity ratios, and shareholder friendly management.
Some of these factors include above - average earnings
per -
share growth rates, above - average return
on equity, excess -
free cash flow, low debt - to - equity ratios, and shareholder - friendly management.
The fund utilizes fundamental, bottom - up research, screening securities
on normalized
free cash flow per share, market opportunity, sales growth, margin outlook and capital deployment to value ideas.
Based
on that 5 - year forecast and IMS Health's tendency to buy back stock (and the reasonable price of that stock before the buyout rumor leaked) it seems likely that
free cash flow per share would have grown by 10 % + annually if IMS Health had stayed a public company.
Fortunately, there was such a huge gap between investors» standard P / E-based * approach vs. my own perspective
on Applegreen's unique float - driven model & underlying
free cash flow - based valuation, that the
shares still trade (despite new all - time highs) well shy of my original $ 8.61 Fair Value
per share.
Our valuation methodology has a three pronged approach:
free cash flow (earnings before interest, taxes, depreciation and amortization, or EBITDA, minus the capital expenditures necessary to grow the business); earnings
per share trends; and private market value (PMV), which encompasses
on and off balance sheet assets and liabilities.